Article Text

PDF
Natriuretic peptides in heart valve disease
  1. S G Ray
  1. Correspondence to:
    Dr Simon Ray
    Department of Cardiology, South Manchester University Hospitals, Wythenshawe Hospital, Manchester M23 9LT, UK; simon.ray{at}smtr.nhs.uk

Abstract

Synthesis and release of B-type natriuretic peptide (BNP) are increased in heart failure, and plasma concentrations provide important therapeutic and prognostic information. Recent studies have shown that BNP concentrations are also increased with disease of the mitral and aortic valves. The extent of the increase is broadly related to the severity of the valve abnormality and the degree of consequent cardiac remodelling. BNP concentrations appear to relate to prognosis in these patients and might have a role in identifying suitable candidates for cardiac surgery. This paper reviews the current literature and identifies areas where further research is required if assessment of BNP is to be of practical use.

  • ANP, atrial natriuretic peptide
  • BNP, B-type natriuretic peptide
  • LV, left ventricular
  • NT-proBNP, N-terminal pro-B-type natriuretic peptide
  • NYHA, New York Heart Association
  • natriuretic peptide
  • mitral valve
  • aortic valve

Statistics from Altmetric.com

Footnotes

  • Published Online First 26 October 2005

  • Competing interests: none declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.